A Glimpse of Bristol-Myers' Portfolio
632263
Late-stage drugs are crucial for a company beset with patent losses.
610431
A brief look back at a group of IPO siblings provides lessons for investors now and in the future.
645823
A company that could put the va-va-voom in your portfolio this Valentine's Day.
496783
Here are a few companies primed for growth.
459925
A stock for dividend investors' watch list.
760357
Biotech funds differ in their make-up, performance, and promise.
174409
The company's lead drug will enter phase 1 trials, bringing potential good fortune to investors.
584007
Investors reward the drugmaker for positive study results.
434277
The market might overlook the drug maker's promising programs.
738382
The drug maker is poised to speed past its rivals.
751523
A new addition to an already successful drug promises good results for investors.
724808
An investigation into the practice of Internet Pharmacies and how they are changing the U.S. pharmaceutical industry.
730107
Can this small drug company compete with the industry's giants?
591674
Bristol-Myers Squibb (nyse: BMY - news - people ) will report third-quarter earnings. Analysts surveyed by Thomson First Call expect the pharmaceutical maker to earn 39 cents per share compared with 47 cents a year ago.
642953
One new stock has left quite a footprint.
324955
This small pharma is quietly growing earnings.
444509
Give your fund portfolio a head-to-toe evaluation.